

Press Release

Matthias Link
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2872
F +49 6172 608-2294
Matthias.Link@fresenius.com
www.fresenius.com

December 20, 2011

Fresenius slightly improves outlook – Constant currency earnings growth of approximately 18% expected

After a strong third quarter, Fresenius expects to achieve excellent fourth quarter earnings growth in 2011. In particular, Fresenius Kabi and Fresenius Helios have continued to perform strongly.

Therefore, Fresenius improves its 2011 earnings outlook slightly and now expects to achieve constant currency net income¹ growth of approximately 18%. Fresenius previously improved its earnings outlook of 15% to 18% constant currency growth to the upper half of this range on November 2, 2011.

Sales growth in constant currency is expected to just reach the targeted c. 6% as current sales at Fresenius Medical Care and Fresenius Vamed remain slightly below expectations. Fresenius Kabi and Fresenius Helios continued to see excellent sales growth and are fully on track to achieve their guidance.

¹ Net income attributable to Fresenius SE & Co. KGaA; adjusted for the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds and the Contingent Value Rights related to the acquisition of APP Pharmaceuticals. Both are non-cash items.

#

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2010, Group sales were approximately €16.0 billion. On September 30, 2011 the Fresenius Group had 145,118 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Dr. Ulf M. Schneider (Chairman), Rainer Baule, Dr. Francesco De Meo,

Dr. Jürgen Götz, Dr. Ben Lipps, Stephan Sturm, Dr. Ernst Wastler

Chairman of the Supervisory Board: Dr. Gerd Krick